Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640484 · ClinicalTrials.gov registry record · Phase 2
Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD
A Phase 2 study of Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
- 15
- Study locations
NCT00640484: Completed Phase 2 study of Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A..
NCT00640484 is a Phase 2 study of Chronic Obstructive Pulmonary Disease that has completed, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 57 participants, below the 1,753-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (97% lower). The trial reports 15 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00640484, a Phase 2 study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by Chiesi Farmaceutici S.p.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to confirm the dose of CHF 4226 (carmoterol) that should be given once a day to patients with COPD in order for the effect to last for 24 hours.
Conditions Studied
Interventions
- DRUG placebo
- DRUG carmoterol (CHF 4226)
- DRUG salmeterol
Study Locations (15)
Arizona
- Horizon Clinical Research Associates, PLLC - Gilbert
- Pulmonary Associates, PA - Phoenix
Oregon
- Clinical Research Institute of Southern Oregon, PC - Medford
- Asthma Allergy Associates - Portland
California
- UCLA David Geffen School of Medicine - Los Angeles
Florida
- University Clinical Research - DeLand, LLC - DeLand
Georgia
- Pulmonary Medicine and Critical Care - Austell
Illinois
- Sneeze, Wheeze & Itch Associates, LLC - Normal
Kentucky
- Commonwealth BioMedical Research - Madisonville
North Carolina
- North Carolina Clinical Research - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00640484 record still lists
NCT00640484 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 1,753-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00640484 lists 15 locations in 13 states (Arizona, Oregon, California).
Frequently Asked Questions
What is clinical trial NCT00640484 about?
NCT00640484 is a clinical study titled "Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD". The purpose of this study is to confirm the dose of CHF 4226 (carmoterol) that should be given once a day to patients with COPD in order for the effect to last for 24 hours.
What is the current status of trial NCT00640484?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2008-04. Estimated completion is 2008-10.
What conditions does trial NCT00640484 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT00640484?
The interventions under investigation include: placebo (DRUG), carmoterol (CHF 4226) (DRUG), salmeterol (DRUG).
Who is sponsoring clinical trial NCT00640484?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00640484 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00640484's enrollment target sits among peer trials
57 60th of 86 higher than 27 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
RECRUITING · Phase 2
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
Biological Effects of Quercetin in COPD Phase II
RECRUITING · Phase 2
-
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
RECRUITING · Phase 2
-
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
RECRUITING · Phase 2
-
Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia